The Metabolic Reality
CKD progression is largely driven by metabolic, dietary, and lifestyle factors. The world's leading kidney disease guideline organizations — KDIGO and KDOQI — both recognize this and recommend very low protein diets supplemented with keto acid analogs as the evidence-based approach for patients at risk of progression.
The Physician Gap
Nephrologists manage CKD through pharmacological intervention — medications, dialysis, and transplantation. Dietary and nutritional management is a separate clinical discipline that nephrology, as a specialty, is not structured to provide. This is not a criticism. It is an accurate description of how specialty medicine works.
In practice, most nephrologists are not yet aware that KDIGO 2024 and KDOQI 2020 changed their dietary recommendations to support very low protein diets with keto acid analogs. Dietary guideline updates travel differently through the medical system than drug trial results. The practical result: most CKD patients cannot learn about this approach from their own specialist — even though their specialist's own guideline organizations recommend it.
The Book Market Gap
More than 30 kidney diet books are published every year. Over the past 20 years, hundreds have been published. Of all of them, only two have any real clinical data — and only one, the Stopping Kidney Disease series, has been validated in human clinical studies using standard methodology, informed consent, and the same clinical endpoints used in kidney disease drug trials.
When a CKD patient looks for dietary guidance, they find a market full of books and programs that give the impression of clinical backing without the evidence. The absence of a proven program is not visible from the outside — it looks like abundance.
The Access Gap
Even when a patient knew what they needed, the product wasn't accessible. Keto acid analogs were prescription-only in most countries, unavailable in the United States entirely, and formulated with high calcium levels that conflict with current NKF guidance for Stage 3-4 patients.
These three gaps — guideline awareness, no proven program, no accessible product — stack on top of each other to create a total absence for the patient who most needs help.
Why Albutrix Ships Free Worldwide
"My personal experience as a kidney patient was being denied access to treatment options based on where I lived. What was available in one country was unavailable in another. Whether my disease progressed or stabilized depended not on the science, but on an accident of geography.
That experience is not unusual. It is the norm for most CKD patients in the world. I built Kidneyhood, and specifically the decision to ship free worldwide without a prescription, as a direct response to that reality. Every patient deserves access to the same clinically proven nutritional support, regardless of where they live or their net worth."
— Lee Hull, Founder
What Kidneyhood Provides
Kidneyhood does not compete with nephrology care. It provides what nephrology care explicitly does not:
- The only clinically proven integrated VLPD + keto acid analog program — studied in human patients, measuring eGFR, BUN, and creatinine
- Albutrix — the only magnesium-based keto acid analog, the only one proven to improve eGFR and achieve BUN targets
- The only kidney disease book series validated in human clinical studies — 6 titles, 5,000+ reviews, #1 Amazon nephrology for 5+ years
- Free worldwide shipping without a prescription — the only globally accessible program of its kind
- Two US and EU patents, six provisional patents, active FDA drug approval pathway
- 4,910+ patients, 20+ countries, 8 years, zero reported adverse events
Kidneyhood is not a supplement company. It is the only organization in the world that has built, proven, and made globally accessible the dietary and nutritional intervention that leading nephrology organizations recommend — and that, until Kidneyhood, did not exist in a form any patient could actually use.
